Rheumatology and immune-dermatology leader, Novartis announced new clinical data from MAXIMISE trial evaluating the efficacy and safety of Cosentyx (secukinumab) in the management of axial manifestations of psoriatic arthritis (PsA).
PsA is a complex disease with multiple manifestations, closely associated with psoriasis. It is part of the inflammatory disease family (spondyloarthritis) which affects up to 50 million people worldwide.
MAXIMISE is a 52-week, double-blind, randomized, placebo-controlled Phase Ⅲb study to evaluate the efficacy and safety of Cosentyx (secukinumab) in the management of PsA axial manifestations. 498 patients with PsA were enrolled in the trial. It met both its primary and secondary endpoint with 63.1% of Cosentyx 300 mg and 66.3% of Cosentyx 150 mg achieving ASAS20 at week 12 (versus 31.3% for placebo). Rapid onset of relief was seen in patients as early as week four.
Cosentyx is first and only fully human biologic that inhibits interleukin-17A, a cornerstone cytokine which cause inflammation and development of PsA, psoriasis and ankylosing spondylitis. Used by 200,000 patients worldwide since used and its safety is backed by robust clinical data. Cosentyx bridges for the first-time treatment of psoriasis, psoriatic arthritis and axial manifestations.
Mr Vinod Arora, Principal Advisor, IGMPI
Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like